Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 21, 2004. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding movements within an employee retirement fund.
Material Changes
The filing details two specific movements in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan:
- July 15, 2004 Movement: The fund's holdings decreased from 19,041,528 to 18,999,764 ADRs at an average price of $40.63.
- July 16, 2004 Movement: The fund's holdings increased from 18,999,764 to 19,061,552 ADRs at an average price of $39.30.
These changes affect the potential interests of directors Dr. J.P. Garnier and Dr. T. Yamada, who are beneficiaries of the discretionary fund alongside other employees.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The scope is limited to regulatory disclosure of director share interests.
Investor Verification Points
- Verify the total aggregate holdings of the US Retirement Savings Plan to assess the scale of director exposure.
- Confirm the specific allocation of shares to Dr. J.P. Garnier and Dr. T. Yamada, as the filing only notes their potential interest in the fund.
- Review the fund's trading activity frequency to understand the volatility of director shareholdings.